Eqrx and absci announce partnership to discover and develop next-generation protein-based drugs

Cambridge, mass., & vancouver, wash.--(business wire)--eqrx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and absci corporation (nasdaq: absi), the drug and target discovery company harnessing deep learning ai and synthetic biology to expand the therapeutic potential of proteins, today announced a discovery collaboration. the partnership will leverage absci's drug creation™ technology for discovery and
ABSI Ratings Summary
ABSI Quant Ranking